235 related articles for article (PubMed ID: 30346511)
1. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
[TBL] [Abstract][Full Text] [Related]
2. Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials-The Ring Study and DREAM.
Steytler J; van der Ryst E; Craig C; Van Baelen B; Nuttall J; van Niekerk N; Mellors J; Parikh U; Wallis C;
Clin Infect Dis; 2023 Feb; 76(3):389-397. PubMed ID: 36189636
[TBL] [Abstract][Full Text] [Related]
3. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
Nel A; van Niekerk N; Kapiga S; Bekker LG; Gama C; Gill K; Kamali A; Kotze P; Louw C; Mabude Z; Miti N; Kusemererwa S; Tempelman H; Carstens H; Devlin B; Isaacs M; Malherbe M; Mans W; Nuttall J; Russell M; Ntshele S; Smit M; Solai L; Spence P; Steytler J; Windle K; Borremans M; Resseler S; Van Roey J; Parys W; Vangeneugden T; Van Baelen B; Rosenberg Z;
N Engl J Med; 2016 Dec; 375(22):2133-2143. PubMed ID: 27959766
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction.
Steytler J; Craig C; van der Ryst E; Van Baelen B; Nuttall J; van Niekerk N; Mellors J; Parikh U; Wallis C;
Clin Infect Dis; 2023 Mar; 76(6):996-1002. PubMed ID: 36345569
[TBL] [Abstract][Full Text] [Related]
6. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
7. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.
Baeten JM; Palanee-Phillips T; Brown ER; Schwartz K; Soto-Torres LE; Govender V; Mgodi NM; Matovu Kiweewa F; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Pather A; Naidoo L; Husnik M; Richardson BA; Parikh UM; Mellors JW; Marzinke MA; Hendrix CW; van der Straten A; Ramjee G; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Mayo A; Scheckter R; Berthiaume J; Livant E; Jacobson C; Ndase P; White R; Patterson K; Germuga D; Galaska B; Bunge K; Singh D; Szydlo DW; Montgomery ET; Mensch BS; Torjesen K; Grossman CI; Chakhtoura N; Nel A; Rosenberg Z; McGowan I; Hillier S;
N Engl J Med; 2016 Dec; 375(22):2121-2132. PubMed ID: 26900902
[TBL] [Abstract][Full Text] [Related]
8. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
[TBL] [Abstract][Full Text] [Related]
9. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.
Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N
AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
[TBL] [Abstract][Full Text] [Related]
11. Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.
McBride JW; Malcolm RK; Dias N; Cameron D; Offord RE; Hartley O; Kett VL; Devlin B; Boyd P
Int J Pharm; 2019 Jun; 564():207-213. PubMed ID: 30999049
[TBL] [Abstract][Full Text] [Related]
12. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.
Palanee-Phillips T; Schwartz K; Brown ER; Govender V; Mgodi N; Kiweewa FM; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Naidoo S; Pather A; Phillip J; Husnik MJ; van der Straten A; Soto-Torres L; Baeten J
PLoS One; 2015; 10(6):e0128857. PubMed ID: 26061040
[TBL] [Abstract][Full Text] [Related]
14. Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.
Penrose KJ; Wallis CL; Brumme CJ; Hamanishi KA; Gordon KC; Viana RV; Harrigan PR; Mellors JW; Parikh UM
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895013
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.
Makanani B; Balkus JE; Jiao Y; Noguchi LM; Palanee-Phillips T; Mbilizi Y; Moodley J; Kintu K; Reddy K; Kabwigu S; Jeenariain N; Harkoo I; Mgodi N; Piper J; Rees H; Scheckter R; Beigi R; Baeten JM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):566-572. PubMed ID: 30383589
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
Parikh UM; Penrose KJ; Heaps AL; Halvas EK; Goetz BJ; Gordon KC; Hardesty R; Sethi R; Schwarzmann W; Szydlo DW; Husnik MJ; Chandran U; Palanee-Phillips T; Baeten JM; Mellors JW;
J Int AIDS Soc; 2021 Nov; 24(11):e25833. PubMed ID: 34762770
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: HIV Drug Resistance Assessment Among Women Who Seroconverted During the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial.
Parikh UM; Penrose KJ; Heaps AL; Sethi R; Goetz BJ; Szydlo D; Chandran U; Palanee-Phillips T; Mgodi NM; Baeten JM; Mellors JW;
J Acquir Immune Defic Syndr; 2024 Jan; 95(1):35-41. PubMed ID: 37732881
[TBL] [Abstract][Full Text] [Related]
18. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
[TBL] [Abstract][Full Text] [Related]
19. Development of dapivirine vaginal ring for HIV prevention.
Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
[TBL] [Abstract][Full Text] [Related]
20. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
